AI assistant
Dr. Lal Pathlabs Limited Interim / Quarterly Report 2021
61783_rns_2021-01-29_6ab3557c-acfd-4cd5-8f82-4ec46f474ec1.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
January 29, 2021
National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Sandra Kurla Complex Sandra (E) Mumbai - 400 051.
Bombay Stock Exchange Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001
Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2020
Dear Sir/Madam,
Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2020.
We request you to please take the same on record.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
�¥ Rajat Kalra
Company Secretary and Legal Head Encl: As above
For Immediate Release January 29, 2021
Dr. Lal PathLabs Limited records revenue of Rs 452.4 Cr in Q3 FY 2020-21
New Delhi, India, January 29, 2021 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2020
Consolidated Performance Highlights: Q3 FY 2020-21 vs Q3 FY 2019-20 Revenue: Rs 452.4 Cr, a growth of 38.0% Normalised EBITDA at Rs 144.6 Cr with margin at 32.0% PBT at Rs 128.9 Cr with margin at 28.5%, and PAT Rs 95.9 Cr with margin at 21.2%
- Operating Revenue increased by 38.0% in Q3 FY21 to Rs. 452.4 Cr vs Rs 327.9 Cr in Q3 FY20
- Covid and Allied contributed 21.6% to Revenue in Q3 FY21 with 5.27 lac RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q3 FY21 is at Rs. 144.6 Cr Vs Rs 88.9 Cr in the same quarter last year
- PBT is at Rs 128.9 Cr in Q3 FY21 vs Rs 73.4 Cr. in Q3 last year
- Profit after Tax in Q3 FY21 at Rs. 95.9 Cr as compared to Rs 54.9 Cr in Q3 last year
- Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board
Financial Overview (Consolidated) in Rs Cr
| Particulars | Q3 FY21 | Q3 FY20 | Gr % | YTD Dec'20 YTD Dec'19 | Gr % | |
|---|---|---|---|---|---|---|
| Revenue | 452.4 | 327.9 | 38.0% | 1150.3 | 1028.7 | 11.8% |
| Expenditure | 313.6 | 245.6 | 836.0 | 742.4 | ||
| EBITDA | 138.8 | 82.3 | 68.7% | 314.3 | 286.3 | 9.8% |
| Adj for Stock BasedCompensation & CSR cost | 5.8 | 6.6 | 18.8 | 15.1 | ||
| Normalised EBITDA | 144.6 | 88.9 | 62.7% | 333.1 | 301.4 | 10.5% |
| Normalised Margins | 32.0% | 27.1% | 29.0% | 29.3% | ||
| Other income | 13.5 | 13.8 | 37.8 | 43.0 | ||
| PBT | 128.9 | 73.4 | 75.6% | 283.6 | 265.1 | 7.0% |
| Margins | 28.5% | 22.4% | 24.7% | 25.8% | ||
| PAT | 95.9 | 54.9 | 74.7% | 211.4 | 195.0 | 8.4% |
| Margins | 21.2% | 16.7% | 18.4% | 19.0% | ||
| EPS (Basic) | 11.44 | 6.56 | 74.4% | 25.23 | 23.48 | 7.4% |
| EPS (Diluted) | 11.41 | 6.55 | 74.2% | 25.16 | 23.42 | 7.4% |
Dr. Lal Pathlabs Limited 12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 1
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pickup Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Prakash Goel Chief Financial Officer Dr. Lal PathLabs Limited
Mittali Bharti Adfactors PR
+91 124 3016500 [email protected]
+91 9871154558 [email protected]
For further information on Dr. Lal PathLabs see www.[lalpathlabs.com](http://www.lalpathlabs.com/)
Safe Harbour
This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Dr. Lal Pathlabs Limited
12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 2